Our pathway-focused analysis demonstrated that the vast majority of the cholesterol-biosynthesis genes were significantly downregulated by the RORγ antagonists in a dose-dependent manner in both TNBC cell lines and tumor organoids (Fig. 3d left two panels). Here, RORC is linked to neoplasm.